FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| washington, D.C. 20 | J54 |
|---------------------|-----|
| | |

| | OIVID APPROVAL | | | | | | |
|-------|--------------------------|--|--|--|--|--|--|
| ОМЕ | OMB Number: 3235-0287 | | | | | | |
| Estin | Estimated average burden | | | | | | |
| hour | hours per response: 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 193

| IIISII UC | don I(b). | | | Filed | | | | | | | | ompany Act o | | | | | | | | |
|--|--|--|-----------------|-----------|---|--|-----|--|--------------------|----------------------------|---|---|--|--|--------|--|--------------------------------|---|--|--|
| | | | | | | 2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [LPTX] | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner | | | | | | | |
| (Last) (First) (Middle) L | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/22/2020 | | | | | | | | Officer (give title Other (specify below) below) | | | | | | |
| | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person | | | | | | | | |
| | | Table | I - No | on-Deriva | tive | Sec | cur | ities | Acc | quired | , Di | sposed of | f, or E | Benefic | ially | / Own | ed | | | |
| 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day) | | | Execution Date, | | | 3. 4. Securities Act Transaction Disposed Of (D) Code (Instr. 8) 5) | | | Acqui f (D) (In | red (A) or str. 3, 4 ar | nd | 5. Amount of Securities Beneficially Owned Following Reported | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | | | |
| | | | | | | | | | | Code | v | Amount | (A) (D) | or Price | . | Transaci (Instr. 3 | ction(s) | | | |
| Common Stock 06/22/20 | | | 020 | 20 | | | P | | 1,750,000 |) A | \$2 | ! 8,476 | | 6,496 | ,496 I | | See footnote ⁽¹⁾ | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | se (Month/Day/Year) if any (Month/Day/Year) 8) | | Code | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | Dei Sed (Ins | 8. Price of Derivative Security (Instr. 5) (Instr. 5) 9. Numb derivativ Securitit Benefici Owned Followin Reporter Transact (Instr. 4) | | Ownershi es Form: Direct (D) or Indirect g (I) (Instr. 4 | | Beneficial Ownership t (Instr. 4) | | |
| | | | | | Code | v | | (A) | (D) | Date Exercis | sable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| | | Reporting Person* | LC | | | | | | | | | | | | | | | | | |
| (Last) | | (First) | (N | liddle) | | | | | | | | | | | | | | | | |

| 1. Name and Address of Reporting Person* PERCEPTIVE ADVISORS LLC | | | | | | | |
|---|-----------------|--------------------------------|----------|----------|--|--|--|
| (Last) 51 ASTO | | (First) 10TH FLOOR | (Middle) | | | | |
| (Street) NEW YO | ORK : | NY | 10003 | | | | |
| (City) | | (State) | (Zip) | | | | |
| PERCE FUND | EPTIVE L LTD | Reporting Person* LIFE SCIENC | | <u>3</u> | | | |
| | RCEPTIVE . | (First) ADVISORS LL | (Middle) | | | | |
| (Street) NEW YO | ORK : | NY | 10003 | | | | |
| (City) | | (State) | (Zip) | | | | |
| 1. Name and Address of Reporting Person* EDELMAN JOSEPH | | | | | | | |
| (Last) C/O PEF | | (First) ADVISORS LL | (Middle) | | | | |

51 ASTOR PLACE, 10TH FLOOR

| (Street) NEW YORK | NY | 10003 |
|-------------------|---------|-------|
| (City) | (State) | (Zip) |

Explanation of Responses:

1. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Remarks:

/s/ Perceptive Life Sciences Master Fund Ltd., By:

Perceptive Advisors LLC, its investment manager By:

Joseph Edelman, its managing

member

/s/ Perceptive Advisors LLC,

By: Joseph Edelman, its 06/24/2020

managing member

/s/ Joseph Edelman 06/24/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.